Event time: 事件时间：
Published: 文章发布：
Key Results
Actual vs Consensus
EPS: $3.29 vs $1.91 estimate, beat+72.3%.Revenue: $1.1B vs $1.0B estimate, beat+7.6%.Profitability and Cash Flow
Period: 2026 Q3 period ended 2026-09-30Revenue: $1.1B; YoY: +41.2%; QoQ: +17.1%Gross profit: $1.1B; Gross margin: 97.6%Operating income: $331M; Operating margin: 29.5%; YoY: +38.6%; QoQ: +116.5%Net income: $206M; GAAP diluted EPS: $1.96; YoY: -1.4%; QoQ: +43.0%Operating cash flow: $395M; Capex: $12M; Free cash flow: $384MCash: $642M; Total debt: $392M; Net cash: $249MOfficial release: Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
核心结果
实际值与市场预期
EPS：$3.29 vs $1.91 预期，高于预期+72.3%。营收：$1.1B vs $1.0B 预期，高于预期+7.6%。财务指标
期间：2026 Q3（截至 2026-09-30）营收：$1.1B；同比：+41.2%；环比：+17.1%毛利润：$1.1B；毛利率：97.6%经营利润：$331M；经营利润率：29.5%；同比：+38.6%；环比：+116.5%净利润：$206M；GAAP 稀释 EPS：$1.96；同比：-1.4%；环比：+43.0%经营现金流：$395M；资本开支：$12M；自由现金流：$384M现金：$642M；总债务：$392M；净现金：$249M
